GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance ...
Emergent BioSolutions sold its Baltimore-Bayview facility to Syngene International for $36.5 million, retaining future manufacturing rights. Emergent BioSolutions Inc. has completed the sale of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results